Evidence map›Paper›PMID 40330967›Full record

ReviewRomanian journal of ophthalmology

Innovative technologies for the treatment of dry age-related macular degeneration (AMD) - modern therapeutic perspectives and their future.

Przemysław Ciszewski, Alicja Drelichowska, Damian Pikor, Emilia Wiśniewska, Michał Azierski

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Przemysław CiszewskiScientific Association of Ophthalmology, Department of Ophthalmology, Silesian Medical University, Katowice, Poland.
Alicja DrelichowskaScientific Association of MedTech at the Center for Remote Learning and Educational Effects Analysis, Faculty of Medical Sciences in Katowice, Silesian Medical University, Katowice, Poland.
Damian PikorDepartment and Clinic of Tropical and Parasitic Diseases, University of Medical Sciences, Poznań, Poland.
Emilia WiśniewskaScientific Association of MedTech at the Center for Remote Learning and Educational Effects Analysis, Faculty of Medical Sciences in Katowice, Silesian Medical University, Katowice, Poland.
Michał AzierskiScientific Association of MedTech at the Center for Remote Learning and Educational Effects Analysis, Faculty of Medical Sciences in Katowice, Silesian Medical University, Katowice, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This review explores modern therapeutic options for the dry form of age-related macular degeneration (AMD), a condition representing one of the most significant challenges in ophthalmology due to its progressive nature and lack of effective treatment. The study discusses innovative approaches, evaluates available methods, and examines the potential of emerging technologies to improve patients' quality of life. Methods: A comprehensive review of current literature was conducted, being focused on therapies for dry AMD, including classical methods such as AREDS/AREDS2 supplementation, molecularly targeted drugs, gene therapy, cell transplants, tissue engineering, nanotechnology, and light-based therapies. Emerging tools leveraging artificial intelligence for personalized treatment and predictive modeling were also evaluated. Results: AREDS/AREDS2 therapies effectively slow disease progression but cannot reverse retinal damage. Advances include molecularly targeted therapies (Pegcetacoplan, Avacincaptad Pegol) that reduce inflammation, gene therapy (HMR59) protecting RPE cells, and mitochondria-targeted drugs (SS-31) mitigating oxidative stress. Using scaffolds, nanoparticles, tissue engineering, and nanotechnology enhances RPE regeneration and drug delivery. Light-based therapies (LLLT, adaptive phototherapy) improve mitochondrial function, while AI aids in predicting disease progression and personalizing treatment. Conclusions: Modern therapeutic approaches for dry AMD provide promising avenues to slow disease progression and protect vision. However, further clinical trials are needed to optimize these strategies, assess long-term outcomes, and expand patient access to effective treatments. These advancements have the potential to significantly improve the quality of life for individuals affected by dry AMD.

Indexed as

Genetic TherapyGeographic AtrophyQuality of LifeHumansTissue EngineeringAI = Artificial IntelligenceAMDAMD = Age-related Macular DegenerationAREDS2 = Age-Related Eye Disease Study 2AREDS = Age-Related Eye Disease StudyATP = Adenosine Triphosphatedry age-related macular degenerationESC(s) = Embryonic Stem Cell(s)FAF = Fundus AutofluorescenceFDA = Food and Drug AdministrationGA = Geographic AtrophyHLA = Human Leukocyte AntigenHRF = Hyperreflective Fociinnovative therapyiPSC(s) = Induced Pluripotent Stem Cell(s)LLLT = Low-Level Laser TherapyMAC = Membrane Attack ComplexnanotechnologyNGF = Nerve Growth FactorOCT = Optical Coherence TomographyPCL = PolycaprolactonePMC = Pentamethyl-6-chromanolRELITE = Regenerative Retinal Laser and Light TherapiesROS = Reactive Oxygen SpeciesRPE = Retinal Pigment EpitheliumsCD59 = Soluble CD59 (complement regulatory protein)SS-31 = Elamipretide (a mitochondria-targeting drug)

Identifiers

PMID40330967
PMCPMC12049644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.